BioSpace News Archive

Lirum Therapeutics, Inc. announced that it has closed a private placement, which resulted in gross proceeds to Lirum of over $7 million, before deducting offering expenses.

Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, and Gwenn M. Hansen, Ph.D., Nurix’s chief scientific officer, will participate in the following conferences in February.

Galapagos NV (Euronext & NASDAQ: GLPG) today announced the topline results from DIVERSITY, a global Phase 3 trial to evaluate the safety and efficacy of filgotinib,100mg or 200mg once daily, during induction and maintenance treatment ofbiologic-naïve and biologic-experienced patients with moderate to severe Crohn’s disease (CD).

Disc Medicine, Inc. announced that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will participate in a fireside chat in a virtual format at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 8:40 a.m. ET.

DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced management will participate at the following investor conferences.

Hyperfine, Inc. announced that Brett Hale will join Hyperfine, Inc. on February 13, 2023 and will serve as Chief Administrative Officer & Chief Financial Officer.

23andMe Holding Co. reported its financial results for the third quarter of its fiscal year 2023, which ended December 31, 2022.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual SVB Securities Global Biopharma Conference taking place from February 14-16, 2023.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2022, recent business highlights and key upcoming catalysts for 2023.

Travere Therapeutics, Inc. announced that Company management will participate in the following upcoming conferences.